| Bioactivity | TM38837 is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist. TM38837 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects. TM38837 reduces propensity for psychiatric side effects[1][2]. | ||||||||||||
| In Vivo | TM38837 (10-100 mg/kg; p.o.) induces a significant increase in freezing behavior at 100 mg/kg[1]. Animal Model: | ||||||||||||
| Name | TM38837 | ||||||||||||
| CAS | 1253641-65-4 | ||||||||||||
| Formula | C30H25Cl2F3N4OS | ||||||||||||
| Molar Mass | 617.51 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Micale V, et al. The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows ReducedFear-Promoting Effects in Mice. Front Pharmacol. 2019 Mar 20;10:207. [2]. Klumpers LE, et al. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol. 2013 Dec;76(6):846-57. |
TM38837
CAS: 1253641-65-4 F: C30H25Cl2F3N4OS W: 617.51
TM38837 is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist. TM38837 shows limited penetranc
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.